The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
What’s to derisk?
The platform proven already last January!
Efficacy has been confirmed!!
Safety Data has already been outstanding and better than they could wish for!
Data coming early!!
You can guess why data would be presented early!
They rushed out a two week dosing trial.
No P1b required now.
Do you not think that perhaps in the background someone significant has already asked for the direction they have taken?
Dr W Tap in US regarded as the number 1 on STS is there since January proving and speaking to US BP.
The rest speaks for itself.
Bella
What you need to remember AVA6k is also showing effect in other indications on top of Soft Tissue Sarcoma.
So they have the availability to out license further indications but secure STS to an early revenue potentially funded via out license of one or more other indications.
“has been confirmed in a patient with soft tissue sarcoma on the trial, and there are further indications of clinical activity in patients across other indications.”
The reality here is that those players of the boards have absolutely no chance of creating doubt with this one as the platform and its first drug is proven beyond doubt.
The numbers and data are about to come in black and white.
Users here will not be of importance or relevance as this has BP written all over it asap.
It will be a designed stage of how that comes about.
The largest issue is potentially monopoly if one player gets all. It could be divided out to several BP’s if that becomes an issue.
These are good issues though to have as in the pie is too large.
Now as Alastair said himself ‘wouldn’t it be good if no MTD was found’
The platform tech is showing just how revolutionarily powerful it is and just how significant that is to a pipeline of drugs not to mention those that are in license with other majors who want toxicity removed from those also.
Huge
They really struggle here to make a Market. Desperately trying to hold it up but not actually making a market.
Just rinse and repeat. No news Mmmmm well it’s a tough market to raise anything especially when it’s so hard to clear them.
Absolutely
pi’s are not important. If they have been wise enough to listen and understand then lucky them.
When it comes to paradigm shifts in tech and drugs then it sorts itself.
The small players pretending to matter become completely silent 🤫
If they can secure it then it will happen.
They given themselves further running room with moving accounting period. No deals means no money.
Cannot do any studies. Can’t pay the discussions and travel times etc to generate further immediate interest to get anything substantial.
NXP004 worthless
NXP002 needs further studies to show it has anything substantial. A few slivers of lung tissues doesn’t gain 10’s millions of upfront cash. Without significant cash or someone buying them it perpetuates around and around.
The moment was 2019/20, they lost it and the company, crew and interest. Let’s put it like this, if this had it then Kissei would have bought it. They haven’t and now they won’t.
They need cash they need more substantial data to drive further interest.
They will wind it up and pass it on for pennies like NXP001 and hide it as a consulting company where shareholders here get zilch but certain management still get the pie.
Keep buying you will get so rich 🤑
I think Alistair and team are very concerned about getting news out in good time and delivering a great updates!!! On how and what.
So
For those that sit here and talk utter tripe everyday deliverance is approaching and yes I believe certain big ticket numbers are scooping up weak holders over this last month.
Clear out traders. Never interested in them anyway. Interested in where this is going for LTH and those that will need care asap.
3 people like your post Soup ? Are they the other 3 accounts you have here on LSE?
Care to explain where you see Full year results? It’s always been half yearly in December and more often the time where they raise cash.
As usual you hide when wrong.
Is anyone surprised that the potential for AVACTA to be approached by BP?
It’s been ongoing with a massive platform which upon confirming that it works back in January and has continued to confirm Precision is now proven 100% along with AVA6k now proving efficacy on tumours!! One particular STS tumour of significance is continuing to shrink! Potentially showing an immune action by the body or AVA6k is doing it alone?
It only had to improve on toxicity to become the got-to for treatment but it’s smashing the doors down all over the place!!
So people are surprised if a BP approach’s now lol 😂
Of course they are coming and it won’t be one will it!
They will all want the platform and 10 billion is peanuts but £30 a share would imo do it!
Obviously we all want maximum but that will take years and a major. Humanity does not have the time and it’s important to hurry this groundbreaking work up.
£30 and I’ll be laughing happy for sure. 2300% is a good return from todays SP.
Roll on data and let’s see what may happen here.
I wouldn’t be surprised if AZ got wind of others coming forward that it pulls them in to come forward also along with others.
I think the litmus moment of catapulting this SP into the 10’s x tables is happening behind the closed doors waiting on that data to be presented before they emerge.
Sound’s immediately like a complete fail!!
Massively overpriced, over hyped mediocre products.
Too expensive now closing deals to be able to sell their product cheaper without others seeing the price.
Like Air New Zealand where you cannot tell what they flog them for to the partner .
This product is too expensive. When it comes to choice fever is better cheaper and available mass market.
This small tiny market, hard work, over priced, mediocre. End of its business plan is a fail!! Imo